Factor VIII clinical trials
Counted the way a researcher would: Factor VIII with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Factor VIII is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2001 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 4
CSL Behring (6) · Children's Hospital Los Angeles (1) · Novo Nordisk A/S (1) · Bioverativ Therapeutics Inc. (1) · Chulalongkorn University (1) · Hospices Civils de Lyon (1) · Beijing Children's Hospital (1)
Often tested with
Tested in the same studies.
Von Willebrand Factor (5) · Antihemophilic factor, human recombinant (3) · Recombinant FVIIa (1) · Homo sapiens whole (1) · Prednisone (1) · Rituximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Factor VIII is the comparator. A study of two new drugs counts under both.
- 2Emicizumab · Dhaka Medical College, Hoffmann-La Roche · next primary completion Apr 2027
Studies
Open first, then newest update. How each study uses Factor VIII is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedPhase 4Novo Nordisk A/SNCT01561391Written as factor VIII
- Preventing Inhibitor Recurrence IndefinitelyActive, not recruitingPhase 4Children's Hospital Los AngelesNCT04621916Written as FVIII
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia ACompletedPhase 3Bioverativ Therapeutics Inc.NCT01181128Written as Factor VIII (rFVIIIFc)
- Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaStatus unknownPhase 4Beijing Children's HospitalNCT03598725Written as Coagulation Factor VIII
- Study of Biostate® in Children With Von Willebrand DiseaseCompletedPhase 3CSL BehringNCT01213446Written as Biostate
- Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand DiseaseCompletedPhase 2/3CSL BehringNCT00941616Written as Biostate®
- Extension Study of Biostate in Subjects With Von Willebrand DiseaseCompletedPhase 3CSL BehringNCT01224808Written as Biostate
- Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody DevelopmentTerminatedPhase 3CSL BehringNCT01445197Written as Biostate
- Study of Biostate® in Children With Hemophilia ACompletedPhase 3CSL BehringNCT01229007Written as Biostate
- Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric PatientsCompletedPhase 4Chulalongkorn UniversityNCT02727647Written as FVIII
- Individually Tailored Prophylaxis in Patients With Severe Hemophilia ATerminatedNot applicableHospices Civils de LyonNCT00995046Written as FVIII
- Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)CompletedPhase 4CSL BehringNCT00168090Written as Blood coagulation Factor VIII and vWF, human
Given beside what is tested · 2 — Factor VIII is usual care or a partner of the new treatment
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02847637Written as Factor VIII (FVIII)
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ACompletedPhase 3Bioverativ Therapeutics Inc.NCT01458106Written as FVIII (PK subgroup only)
As the comparator · 3 — what is tested is compared with Factor VIII
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06998524Written as Factor VIII (FVIII) Concentrates
- Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A PatientsNot yet recruitingPhase 2/3Dhaka Medical CollegeNCT06938659Written as Factor VIII (FVIII)
- Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia ACompletedPhase 2CSL BehringNCT00879541Written as Biostate® [RP]
Codes
What other systems call Factor VIII · ClinicalTrials.gg INT007470
- MeSH (NLM) D005169Factor VIIIOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005169 | Factor VIII | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.